<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00042809</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02477</org_study_id>
    <secondary_id>IDD #01-35</secondary_id>
    <secondary_id>U01CA069853</secondary_id>
    <secondary_id>CDR0000069472</secondary_id>
    <nct_id>NCT00042809</nct_id>
  </id_info>
  <brief_title>Erlotinib, Trastuzumab, and Paclitaxel in Treating Patients With Advanced Solid Tumors</brief_title>
  <official_title>Phase I Study To Determine The Safety, Tolerance And Preliminary Antineoplastic Activity Of Combined EGFR (erbB1) And HER2 (erbB2) Blockade, With OSI-774 And Trastuzumab, In Combination With Weekly Paclitaxel</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Phase I trial to study the effectiveness of combining erlotinib and trastuzumab with&#xD;
      paclitaxel in treating patients who have advanced solid tumors. Biological therapies such as&#xD;
      erlotinib may interfere with the growth of the tumor cells and slow the growth of the tumor.&#xD;
      Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or&#xD;
      deliver tumor-killing substances to them without harming normal cells. Drugs used in&#xD;
      chemotherapy use different ways to stop tumor cells from dividing so they stop growing or&#xD;
      die. Combining erlotinib and trastuzumab with paclitaxel may kill more tumor cells&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine the safety, quantitative and qualitative toxic effects, maximum tolerated dose,&#xD;
      and dose-limiting toxic effects of erlotinib when combined with paclitaxel and trastuzumab&#xD;
      (Herceptin) in patients with advanced solid tumors.&#xD;
&#xD;
      II. Determine the relevant pharmacokinetic interactions between these agents in these&#xD;
      patients.&#xD;
&#xD;
      III. Determine, preliminarily, the antitumor activity of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label, non-randomized, multicenter, dose-escalation study of&#xD;
      erlotinib.&#xD;
&#xD;
      Intermittent schedule: Patients receive paclitaxel IV over 1 hour followed 30 minutes later&#xD;
      by trastuzumab (Herceptin) IV over 30 minutes on days 1, 8, and 15 of each course. Patients&#xD;
      also receive oral erlotinib once daily on days 3-28 of course 1 and on days 1-28 of&#xD;
      subsequent courses. Courses repeat every 28 days in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of erlotinib until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2&#xD;
      of 3 or 2 of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      Continuous schedule: Once the MTD is determined using the intermittent schedule, an&#xD;
      additional 12 patients are accrued to study the tolerability of a continuous schedule&#xD;
      comprising paclitaxel and trastuzumab as above on days 1, 8, 15, and 22 and oral erlotinib&#xD;
      once daily on days 3-28 during course 1 and on days 1-28 of subsequent courses using the same&#xD;
      dose-escalation scheme as above. Courses repeat as above.&#xD;
&#xD;
      Patients are followed every 30 days.&#xD;
&#xD;
      PROJECTED ACCRUAL: A maximum of 40 patients will be accrued for this study within 10-13.3&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2002</start_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximally tolerated dose (MTD), graded according to the National Cancer Institute Common Toxicity Criteria (NCI CTC) v2.0</measure>
    <time_frame>Up to day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Response rates, as assessed by the Response Evaluation Criteria in Solid Tumors (RECIST)</measure>
    <time_frame>Up to 6 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events, graded according to the NCI CTC v2.0</measure>
    <time_frame>Up to 30 days after last study treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Treatment (paclitaxel, trastuzumab, erlotinib hydrochloride)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See detailed description.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (paclitaxel, trastuzumab, erlotinib hydrochloride)</arm_group_label>
    <other_name>Anzatax</other_name>
    <other_name>Asotax</other_name>
    <other_name>TAX</other_name>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>trastuzumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (paclitaxel, trastuzumab, erlotinib hydrochloride)</arm_group_label>
    <other_name>anti-c-erB-2</other_name>
    <other_name>Herceptin</other_name>
    <other_name>MOAB HER2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib hydrochloride</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Treatment (paclitaxel, trastuzumab, erlotinib hydrochloride)</arm_group_label>
    <other_name>CP-358,774</other_name>
    <other_name>erlotinib</other_name>
    <other_name>OSI-774</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (paclitaxel, trastuzumab, erlotinib hydrochloride)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (paclitaxel, trastuzumab, erlotinib hydrochloride)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed metastatic solid tumor for which there are no effective&#xD;
             standard treatment options&#xD;
&#xD;
          -  HER2 positive (1+ to 3+)&#xD;
&#xD;
          -  Tumor has a high likelihood of expressing epidermal growth factor receptor (EGFR)&#xD;
&#xD;
          -  No evidence of leptomeningeal disease or brain metastases unless previously treated,&#xD;
             currently asymptomatic, and off both antiepileptics and dexamethasone&#xD;
&#xD;
               -  Patients with treated brain metastases are eligible if they are without any&#xD;
                  clinical change in their brain disease status for at least 4 weeks after whole&#xD;
                  brain irradiation&#xD;
&#xD;
          -  Performance status - ECOG 0-2&#xD;
&#xD;
          -  Performance status - Karnofsky 60-100%&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  AST/ALT no greater than 2.5 times upper limit of normal (ULN) (5 times ULN if liver&#xD;
             has tumor involvement)&#xD;
&#xD;
          -  Creatinine normal&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
          -  LVEF more than 50% by radionuclide ventriculogram or MUGA scan&#xD;
&#xD;
          -  No significant cardiovascular disease&#xD;
&#xD;
          -  No prior congestive heart failure requiring therapy&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No gastrointestinal tract disease resulting in an inability to take oral medication or&#xD;
             a requirement for IV alimentation&#xD;
&#xD;
               -  Patients who are unable to swallow tablets and/or who have silicon-based G-tubes&#xD;
                  may dissolve the tablets in distilled water&#xD;
&#xD;
          -  No active peptic ulcer disease&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No known or suspected hypersensitivity to paclitaxel&#xD;
&#xD;
          -  No prior allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to erlotinib or other study agents&#xD;
&#xD;
          -  No concurrent active infection&#xD;
&#xD;
          -  No other concurrent medical condition that would preclude study participation&#xD;
&#xD;
          -  No persistent grade 2 or greater neurotoxicity/neuropathy from any cause&#xD;
&#xD;
          -  No psychiatric disorders or altered mental status that would preclude study&#xD;
             participation&#xD;
&#xD;
          -  No other concurrent immunotherapy&#xD;
&#xD;
          -  No concurrent cytokine growth factors (e.g., colony-stimulating factors)&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for mitomycin or nitrosoureas) and&#xD;
             recovered&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No concurrent hormonal therapy except megestrol as an appetite stimulant or&#xD;
             luteinizing hormone-releasing hormone agonists for prostate cancer&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
          -  No prior surgical procedures affecting absorption&#xD;
&#xD;
          -  No prior EGFR-targeting therapy&#xD;
&#xD;
          -  No other concurrent experimental medications or other specific antitumor therapy&#xD;
&#xD;
          -  No concurrent immunosuppressant therapy&#xD;
&#xD;
          -  No concurrent antiarrhythmic therapy for a ventricular arrhythmia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Muralidhar Beeram</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Therapy and Research Center at The UT Health Science Center at San Antonio</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Therapy and Research Center at The UT Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>August 5, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>January 23, 2013</last_update_submitted>
  <last_update_submitted_qc>January 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

